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Case RepoRt
Hyperpolarised 13C MRI: a new horizon for non-invasive 
diagnosis of aggressive breast cancer
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Case pResentatIon
A 40-year-old nulliparous female presented with a right 
breast lump. She had no known family history of breast 
or ovarian cancer. On examination there was a palpable 
area of indeterminate nodularity in the upper outer quad-
rant of the right breast. There was no palpable axillary 
lymphadenopathy.
InVestIGatIons
Mammography, ultrasound, and dynamic contrast 
enhanced MRI were performed for diagnosis and 
staging. A HP-MRI study (as described below) was 
then performed prior to treatment. Ethical permission 
was granted (Research Ethics Committee (REC) refer-
ence number 17/LO/0431 ;  ClinicalTrials. gov Identifier: 
NCT03687645 ) and written informed consent obtained.
A fluid-path was filled with [1-13C] pyruvate under 
aseptic conditions.3 The assembled path was loaded into 
a hyperpolariser unit (SPINLab, GE Healthcare, Chicago, 
Il) and irradiated with microwaves for 2 h, achieving a 
final [1-13C] pyruvate polarisation of 35%. Subsequently, 
the sample was dissolved in 38 ml of sterile water, and 
neutralized with 17.5 g sterile trometamol buffer solu-
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abstRaCt
Hyperpolarised 13C MRI (HP-MRI) is a novel imaging technique that allows real-time analysis of metabolic pathways 
in vivo.1 The technology to conduct HP-MRI in humans has recently become available and is starting to be clinically 
applied. As knowledge of molecular biology advances, it is increasingly apparent that cancer cell metabolism is related 
to disease outcomes, with lactate attracting specific attention. 2 Recent reviews of breast cancer screening programs 
have raised concerns and increased public awareness of over treatment. The scientific community needs to shift focus 
from improving cancer detection alone to pursuing novel methods of distinguishing aggressive breast cancers from 
those which will remain indolent. HP-MRI offers the opportunity to identify aggressive tumour phenotypes and help 
monitor/predict therapeutic response. Here we report one of the first cases of breast cancer imaged using HP-MRI 
alongside correlative conventional imaging, including breast MRI.
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The patient was positioned supine with an intravenous (IV) 
cannula placed in the left antecubital fossa, in a 3T PET-MRI 
(Biograph, Siemens, Erlangen, Germany) with custom-de-
signed 13C clamshell transmit and two (anterior and posterior) 
7-channel 1 h/13C receive phased array coils (RAPID Biomed-
ical GmbH).
Sagittal and coronal 1H T2 weighted images were acquired for 
tumour localisation using a turbo spin echo sequence with the 
following parameters: repetition time = 5000 ms, effective echo 
time = 80 ms, slice thickness = 5 mm, number of slices = 27, 
field-of-view (sagittal) = 320 x 320 mm, field-of-view (coronal) 
= 360 x 360 mm, echo train length = 11, number of signal aver-
aging = 2, fat suppression technique: spectrally adiabatic inver-
sion recovery.
13C chemical shift imaging (CSI) was planned as a single slice 
acquisition (covering the tumour) with slice positioning guided 
by the 1H T2 weighted images and prior MRI and to minimise 
potential for wrap artefact. The 13C receiver bandwidth was 
centred using a reference phantom containing 1 ml of 8M 13C-
urea (repetition time = 80 ms, time of echo = 3 ms, flip angle = 
10o, bandwidth = 10,000 Hz, field-of-view=160 x 160 mm, slice 
thickness = 30 mm, acquisition matrix = 10×10, reconstruction 
matrix = 16×16). 40 ml of hyperpolarised [1-13C] pyruvate was 
then injected at 5 ml s−1 followed by a 20 ml normal saline flush 
at 3 ml s−1. To account for circulation time 13C CSI measure-
ments were commenced at 25 sec after start of injection. Sequen-
tial CSI was acquired every 10 s for 2 min.
13C CSI data were analysed (MATLAB 2016; MathWorks Inc., 
Natick, MA). The individual free induction decays across the CSI 
grid were apodised with an exponential 5 Hz filter in the time 
domain and then Fourier transformed. Spectral peak (pyruvate 
and lactate) areas were then calculated to produce metabolic 
maps (pyruvate and lactate).
ResuLts
Mammography diagnosed a right-sided 90 mm area of micro-
calcification within which was an ill-defined mass, the latter 
only visible on the medial lateral oblique (MLO) view (Figure 1). 
Ultrasound revealed an irregular hypoechoic mass measuring 20 
mm in the right upper outer quadrant, suspicious for malignancy 
(Figure 2). The right axilla contained a pathological 7 mm lymph 
node with an obliterated hilum. Dynamic contrast enhanced 
MRI demonstrated right-sided multicentric disease (i.e. tumour 
extending beyond one quadrant) (Figure 3).
Node positive breast cancer was confirmed histologically via US 
guided core biopsy of the breast and axillary masses, diagnosing 
a Grade two invasive ductal carcinoma Luminal A. Stereo guided 
vacuum assisted biopsy of microcalcification 3 cm remote from 
the index biopsy revealed high grade ductal carcinoma in situ 
(DCIS), establishing disease extent of 90 mm.
Figure 4a the T2 weighted coronal localiser image demonstrates 
the anatomical location of the multicentric tumour within the 
slice acquired for HP-MRI. The tumour is highlighted with 
arrowheads. It is locally aggressive and invades the chest wall. 
Figure  4b shows the distribution of [1-13C] pyruvate signal 
within the breast cancer. Figure  4c demonstrates the corre-
sponding 13C-lactate map, showing conversion of pyruvate to 
lactate via appearance of high signal (red). Maps presented are 
from the first CSI acquisition (at 25 sec post injection).
Figure 5b presents four spectra from the tumour area acquired 
25 sec after injection, and Figure  5c the summed spectrum, 
derived from the addition of the four spectra (Figure 5b) across 
the tumour, showing the [1-13C]-pyruvate signal (~171 ppm), 
the [1-13C]-pyruvate-hydrate signal (~179 ppm) and [1-13C]-lac-
tate signal (~184 ppm).
Figure  6 shows the summed 13C spectrum from the region of 
interest (four voxels) in the tumour acquired at six different 
points after the injection: first measurement at 25 sec, second 
measurement at 35 sec, third measurement at 45 sec, fourth 
measurement 55 sec, fifth measurement 65 sec, sixth measure-
ment 75 sec. Figure  6b illustrates the temporal changes of the 
lactate and pyruvate signal of the summed spectrum during the 
first six measurements following the [1-13C] pyruvate injection.
DIsCussIon
Cancer cells generate energy via elevated glycolysis with 
enhanced conversion of pyruvate to lactate, metabolism that 
Figure 1. (a)(Medial Lateral Oblique) MLO and (b) (Cranio-
caudal) CC mammographic views of the right breast demon-
strating extensive malignant micro calcification (outlined with 
white arrowheads) and an ill-defined mass (red star) on the 
MLO view.
Figure 2. Corresponding sonographic image shows an irreg-
ular hypoechoic 2 cm likely malignant mass (a) with likely 
pathological right axillary lymph node (b).
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is markedly different from normal non-proliferative cells.4 
Highly glycolytic cancer cells prevent intracellular acidifi-
cation by excreting the glycolytic end-products lactate and 
H + via the monocarboxylate transporters 1 (MCT1) and 
4 (MCT4).5 Currently, it is believed that the acidic tumour 
microenvironment supports aggressive development via 
excessive growth, increased survival, migration, invasion, 
and angiogenesis.1 Moreover, monocarboxylate transporter 
(MCT) one is known to be raised in highly proliferative 
ER-negative breast tumours (compared with ER-positive 
cases with low proliferation), and, furthermore, is associ-
ated with poor survival.5 Hence, imaging lactate production 
via HP-MRI may be a route to identification of aggressive 
tumours and more accurate outcome prediction.
HP-MRI has already been applied successfully in animal 
models to assess tumour development and therapeutic 
response.6 In these studies, the metabolic rate of hyperpola-
rised pyruvate reflects activity of MCT transporters in breast 
cancer.7
Figure 3. MRI of extensive multicentric right-sided breast cancer in the prone position (a) T1 weighted axial image of upper part of 
breast (b) 3D MIP sagittal image of the 2 mins contrast enhanced images showing the extent of malignant disease in the breast. 
(c) 2 min contrast enhanced T1 subtracted axial image of the upper part of the breast (d) T1 post contrast reconstructed coronal 
image of the tumour. The regions of tumour imaged with HP MRI are highlighted with white arrowheads.
Figure 4. HP-MRI: Coronal T2 weighted MRI with rectangular 
13C metabolite colour map superimposed. Red denotes regions of 
highest metabolite concentration whereas blue denotes the lowest. (a) T2 weighted coronal image of the tumour. The regions 
of tumour are highlighted with white arrowheads. The respective metabolic maps are, (b); pyruvate map, and (c); lactate map. 
Images are from 13C CSI first acquisition.
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Figure 5. HP-MRI: (a) Coronal T2 weighted image with spectroscopic grid. The black square over the tumour denotes the location 
of the four spectra presented in (b). (b) Four spectra across the black square in the tumour area acquired 25 sec after injection. 
(c) Summed spectrum, derived from the addition of the four spectra (b) across the tumour, with the [1-13C] pyruvate signal (~171 
ppm), the [1-13C] pyruvate-hydrate signal (~179 ppm) and [1-13C]-lactate signal (~184 ppm).
Figure 6. (a) Six summed spectra acquired at six different points after the injection: first measurement at 25 sec, second measure-
ment at 35 sec, third measurement at 45 sec, fourth measurement at 55 sec, fifth measurement at 65 sec, sixth measurement 75 
sec. (b) The peak areas of lactate and pyruvate over time. The pyruvate peak area was divided by four for ease of view.
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We report one of the first cases of in vivo non-invasive metabolic 
assessment of breast cancer using [1-13C] pyruvate HP-MRI and 
correlate the findings with conventional imaging techniques. 
DCE MRI provided an anatomical map of disease, and is the best 
generally available method to assess disease extent. However, 
it depicts breast tissue vascularity, localising increased tumour 
angiogenesis. As expected, the HP-MRI pyruvate map (which 
represents delivery via blood flow) appears similar to the DCE 
MRI image at 2 min. However, areas of increased signal on DCE 
and HP-MRI pyruvate maps do not occur in tumour exclusively, 
as normal dense breast parenchyma may also be associated with 
relatively increased blood flow/volume. The lactate map demon-
strates areas where pyruvate was converted to lactate. The highest 
concentration of lactate is seen within the tumour. There is some 
signal seen outside the breast on both pyruvate and lactate maps. 
Signal outside of the CSI region of interest may wrap into this 
region, but signal within this area will be correctly spatially local-
ised. The metabolite signals that we observe do correspond with 
the position of the tumour seen on the conventional T2 MRI. 
Wrap around artefact is a current limitation when scanning 
the body using the single slice CSI sequence and coil setup. The 
artefact could be reduced by acquiring images with a dedicated 
breast coil.
In conclusion, we present a case of a young female with extensive 
Grade two ductal carcinoma. Her diagnostic work up included 
all the standard investigations and highlighted the importance 
of a multimodality approach to accurately map the anatomical 
extent of disease. The addition of HP-MRI to this case provided 
proof-of-concept for non-invasive in-vivo metabolic assessment 
of human breast tumour and the potential of identifying aggres-
sive cancers. As this technology is currently in early Phase clin-
ical translation, the information from HP-MRI was not directly 
used change patient management in this case. However, the 
patient did elect for a mastectomy and adjuvant chemotherapy. 
Clinical studies are now needed to determine if 13C HP-MRI 
lactate assessment, as hypothesised by pre-clinical metabolic 
studies, can indeed differentiate aggressive and more indolent 
breast tumours in patients. If successful, HP-MRI could become 
a powerful tool to personalise breast cancer management.
LeaRnInG poInts
1. HP MRI is a new hybrid technique that allows real-time, 
non-invasive assessment of cancer cells behaviour. We 
have shown it is feasible to image breast cancer using 
HP MRI.
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